Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC).

BCG is the gold standard in management of high-risk non-muscle invasive bladder cancer (HRNMIBC). However, in patients who fail BCG, there are few effective intrasvesical options. This review aims to explore standard and emerging therapies in HRNMIBC.

A non-systematic literature review was performed using Medline and PubMed. Literature focused on HRNMIBC and BCG failure studies, with particular attention to Phase II and III clinical trials.

The only FDA approved therapy for BCG failure patients in Valrubicin. Patients with HRNMIBC and BCG failure patients are at increased risk for progression and death from bladder cancer. There are a variety of clinical trials exploring different therapeutic approaches such as immunotherapy, vaccines, radiotherapy, and gene therapy. These trials are showing some promise in the early reporting phase.

Despite limited intravesical treatment options in BCG failure patients, there are several promising therapies currently being developed and several with promising early results.

World journal of urology. 2018 Dec 04 [Epub ahead of print]

Ryan P Werntz, Brittany Adamic, Gary D Steinberg

Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA. ., Section of Urology, Department of Surgery, The University of Chicago Medicine, Chicago, 5841 S. Maryland Avenue, MC 6038, Chicago, IL, 60637, USA.